Watchlist Price Alert

Lyra Therapeutics Inc. (LYRA)

NASDAQ: LYRA · Real-Time Price · USD

11.51

1.06 (10.14%)

At close: Jun 23, 2025, 3:59 PM

11.71

1.69%

After-hours: Jun 23, 2025, 07:55 PM EDT

10.14% (1D)

Bid	10.76
Market Cap	15.25M
Revenue (ttm)	1.19M
Net Income (ttm)	-79.53M
EPS (ttm)	-60.5
PE Ratio (ttm)	-0.19
Forward PE	-0.54
Analyst	Hold

Ask	11.8
Volume	64,689
Avg. Volume (20D)	675,200
Open	10.15
Previous Close	10.45
Day's Range	10.15 - 11.91
52-Week Range	3.81 - 37.50
Beta	0.01

About LYRA

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol LYRA

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for LYRA stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Why Price Moved

3 weeks ago

+310.75%

Lyra Therapeutics shares are trading higher after ... Unlock content with Pro Subscription

7 months ago

-28.07%

Lyra Therapeutics shares are trading lower after the company reported worse-than-expected Q3 sales results.

News

1 week ago · seekingalpha.com

Lyra Therapeutics: Regulatory Pathway For Non-Polyp Patients, An Underappreciated Catalyst

Lyra Therapeutics has lost >90% of its value since announcing the failed ENLIGHTEN-1 trial, despite the recent announcement of a clearly positive ENLIGHTEN-2. Considering a clearly positive phase 3, s...

1 week ago · zacks.com

Lyra Therapeutics (LYRA) Upgraded to Buy: Here's Why

Lyra Therapeutics (LYRA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

2 weeks ago · zacks.com

Lyra Stock Soars 356% in a Week on Strong Rhinosinusitis Study Success

LYRA skyrockets 356% after its lead nasal implant, LYR-210, meets key goals in a pivotal phase III chronic rhinosinusitis study.

3 weeks ago · finbold.com

This penny stock just spiked 550% in a day; Time to buy?

Lyra Therapeutics (NASDAQ: LYRA) ‘s shares surged 550% in pre-market trading on Monday following a breakthrough in its drug trials.

3 weeks ago · benzinga.com

Why Is Lyra Therapeutics Stock Surging Over 400% On Monday?

Lyra Therapeutics, Inc. LYRA released results on Monday from the ENLIGHTEN 2 Phase 3 trial of LYR-210 in adult patients with Chronic Rhinosinusitis (CRS).

1 month ago · zacks.com

Lyra Therapeutics, Inc. (LYRA) Reports Q1 Loss, Lags Revenue Estimates

Lyra Therapeutics, Inc. (LYRA) came out with a quarterly loss of $0.12 per share versus the Zacks Consensus Estimate of a loss of $0.15. This compares to loss of $0.35 per share a year ago.